Question 1

What is ATI-1801?

Accepted Answer

ATI-1801 is a Other.

Question 2

How often does ATI-1801 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 7 articles.

Question 3

When was ATI-1801 first tracked by Ergen?

Accepted Answer

First tracked on Jul 03, 2026.

Question 4

When was ATI-1801 last mentioned in news?

Accepted Answer

Last active on Jul 04, 2026.

Question 5

What is ATI-1801's current news sentiment?

Accepted Answer

Aggregate sentiment score: 20 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is ATI-1801 in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving ATI-1801?

Accepted Answer

Appili Therapeutics VXV-01 Contract Terminated (Jul 03, 2026, 7 articles).

Question 8

How did the "Appili Therapeutics VXV-01 Contract Terminated" event impact ATI-1801?

Accepted Answer

ATI-1801 is a Priority Review Voucher eligible program targeting cutaneous leishmaniasis that Appili Therapeutics is now focusing on to maximize value after the contract termination.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.